MX2022002728A - Composiciones y metodos para el tratamiento de infecciones virales. - Google Patents

Composiciones y metodos para el tratamiento de infecciones virales.

Info

Publication number
MX2022002728A
MX2022002728A MX2022002728A MX2022002728A MX2022002728A MX 2022002728 A MX2022002728 A MX 2022002728A MX 2022002728 A MX2022002728 A MX 2022002728A MX 2022002728 A MX2022002728 A MX 2022002728A MX 2022002728 A MX2022002728 A MX 2022002728A
Authority
MX
Mexico
Prior art keywords
viral infections
treatment
compositions
methods
binding peptide
Prior art date
Application number
MX2022002728A
Other languages
English (en)
Inventor
Alain Noncovich
Allen Borchardt
Zhi- Yong Chen
Jason Cole
Simon Doehrmann
Wanlong Jiang
Thanh Lam
James M Balkovec
Daniel C Bensen
Thomas P Brady
Quyen- Quyen Thuy Do
Leslie W Tari
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of MX2022002728A publication Critical patent/MX2022002728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las composiciones y métodos para el tratamiento de infecciones virales incluyen conjugados que contienen inhibidores de neuraminidasa viral (por ejemplo, zanamivir, peramivir o análogos de estos) unidos a un monómero de Fc, un dominio Fc y un péptido de unión a Fc, una proteína albúmina o péptido de unión a albúmina. En particular, los conjugados pueden utilizarse en el tratamiento de infecciones virales (por ejemplo, infecciones virales de influenza).
MX2022002728A 2019-09-06 2020-09-08 Composiciones y metodos para el tratamiento de infecciones virales. MX2022002728A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962897036P 2019-09-06 2019-09-06
US201962941405P 2019-11-27 2019-11-27
US201962948143P 2019-12-13 2019-12-13
US202062959857P 2020-01-10 2020-01-10
US202062966500P 2020-01-27 2020-01-27
US202062970491P 2020-02-05 2020-02-05
US202062984705P 2020-03-03 2020-03-03
US202062988304P 2020-03-11 2020-03-11
US202063032488P 2020-05-29 2020-05-29
US202063062377P 2020-08-06 2020-08-06
PCT/US2020/049772 WO2021046549A1 (en) 2019-09-06 2020-09-08 Compositions and methods for the treatment of viral infections

Publications (1)

Publication Number Publication Date
MX2022002728A true MX2022002728A (es) 2022-08-04

Family

ID=74852729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002728A MX2022002728A (es) 2019-09-06 2020-09-08 Composiciones y metodos para el tratamiento de infecciones virales.

Country Status (18)

Country Link
US (3) US20210220478A1 (es)
EP (1) EP4025256A4 (es)
JP (1) JP2022546609A (es)
KR (1) KR20220088527A (es)
CN (1) CN114980933A (es)
AU (1) AU2020342649A1 (es)
BR (1) BR112022004058A2 (es)
CA (1) CA3153359A1 (es)
CL (1) CL2022000531A1 (es)
CO (1) CO2022003078A2 (es)
CR (1) CR20220138A (es)
EC (1) ECSP22026797A (es)
IL (1) IL290792A (es)
MX (1) MX2022002728A (es)
PE (1) PE20221443A1 (es)
TW (1) TW202122117A (es)
WO (1) WO2021046549A1 (es)
ZA (1) ZA202203681B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194983A (zh) 2018-09-06 2021-07-30 奇达拉治疗公司 用于治疗病毒感染的组合物及方法
EP4192510A1 (en) 2020-08-06 2023-06-14 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
EP4192512A1 (en) 2020-08-06 2023-06-14 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
EP4304659A1 (en) 2021-03-11 2024-01-17 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy
WO2023125806A1 (zh) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途
WO2024010810A2 (en) * 2022-07-05 2024-01-11 Cidara Therapeutics, Inc. Fc conjugates including an inhibitor of cd73 and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901081T2 (xx) 1996-11-14 1999-08-23 Biota Scientific Management Pty.Ltd. Y�ntem ve bu y�ntemde kullan�lan yeni bile�imler.
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6456356B2 (ja) 2013-03-15 2019-01-23 ジェネンテック， インコーポレイテッド ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法
WO2017046625A1 (en) 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
WO2018128826A1 (en) * 2017-01-06 2018-07-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
CN113194983A (zh) * 2018-09-06 2021-07-30 奇达拉治疗公司 用于治疗病毒感染的组合物及方法

Also Published As

Publication number Publication date
US20210220478A1 (en) 2021-07-22
ZA202203681B (en) 2023-11-29
PE20221443A1 (es) 2022-09-21
IL290792A (en) 2022-04-01
CL2022000531A1 (es) 2022-10-28
CO2022003078A2 (es) 2022-07-08
US11510992B1 (en) 2022-11-29
WO2021046549A8 (en) 2021-05-20
WO2021046549A1 (en) 2021-03-11
TW202122117A (zh) 2021-06-16
ECSP22026797A (es) 2022-05-31
EP4025256A1 (en) 2022-07-13
BR112022004058A2 (pt) 2022-05-31
US20230398226A1 (en) 2023-12-14
KR20220088527A (ko) 2022-06-27
CR20220138A (es) 2022-07-28
AU2020342649A1 (en) 2022-03-24
CA3153359A1 (en) 2021-03-11
EP4025256A4 (en) 2023-12-13
JP2022546609A (ja) 2022-11-04
CN114980933A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
PH12021550822A1 (en) Compositions and methods for the treatment of viral infections
MX2022002728A (es) Composiciones y metodos para el tratamiento de infecciones virales.
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
CL2018002825A1 (es) Vacuna contra vrs
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
EP3967323A3 (en) Hiv vaccine
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
BR112013028679A2 (pt) inibidores do vírus da hepatite c
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
EA202091113A1 (ru) Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
WO2017164678A3 (ko) 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.